<?xml version='1.0' encoding='utf-8'?>
<document id="28203684"><sentence text="Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study." /><sentence text="Oral administration of crushed ticagrelor tablets turned out to be an efficacious method that improves its pharmacokinetics and pharmacodynamics"><entity charOffset="31-41" id="DDI-PubMed.28203684.s2.e0" text="ticagrelor" /></sentence><sentence text=" This strategy, however, is unlikely to eliminate the drug-drug interaction in patients receiving intravenous morphine, as the impairment of the P2Y12 inhibitor absorption related to decreased propulsive motility of the gastro-intestinal tract is the most likely mechanism of interaction"><entity charOffset="110-118" id="DDI-PubMed.28203684.s3.e0" text="morphine" /></sentence><sentence text=" Thus, we designed a pharmacokinetic and pharmacodynamic study setting the feasibility of platelet inhibition with a loading dose of ticagrelor given as crushed tablets sublingually compared with two other ticagrelor loading dose administration strategies: integral tablet given orally and crushed tablet given orally in patients with unstable angina" /><sentence text=" Ticagrelor and its metabolite AR-C124900XX plasma concentration was evaluated in nine time points (time frame of 6 hours) using liquid chromatography coupled with mass spectrometry; platelet reactivity was evaluated using multiple electrode aggregometry" /><sentence text=" The area under the plasma concentration-time curve for ticagrelor and AR-C124900XX was significantly higher in patients treated with crushed tablets given orally compared with crushed tablets given sublingually only within the first hour after loading dose (936" /><sentence text="9 ± 898" /><sentence text="0 vs 368" /><sentence text="0 ± 422" /><sentence text="4, p=0" /><sentence text="042 and 103" /><sentence text="4 ± 120" /><sentence text="8 vs 31" /><sentence text="3 ± 43" /><sentence text="9, p=0" /><sentence text="031, respectively)" /><sentence text=" Moreover, we showed significantly stronger platelet inhibition in patients receiving crushed ticagrelor orally vs"><entity charOffset="94-104" id="DDI-PubMed.28203684.s17.e0" text="ticagrelor" /></sentence><sentence text=" sublingually at 30 and 45 min after the loading dose (p=0" /><sentence text="024 and p=0" /><sentence text="016, respectively)" /><sentence text=" Therefore, the administration strategy of ticagrelor determines the pharmacokinetic and pharmacodynamic profile of both ticagrelor and its active metabolite AR-C124900XX" /><sentence text="" /></document>